# The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease

> **NCT02453607** · — · UNKNOWN · sponsor: **Ernest Seidman** · enrollment: 225 (estimated)

## Conditions studied

- Inflammatory Bowel Disease
- Crohn's Disease

## Interventions

- **DRUG:** Infliximab
- **DRUG:** thiopurine

## Key facts

- **NCT ID:** NCT02453607
- **Lead sponsor:** Ernest Seidman
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11-17
- **Primary completion:** 2019-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2017-02-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02453607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02453607, "The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02453607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*